Skip to main content
. 2022 Sep 5;12:15078. doi: 10.1038/s41598-022-18790-9

Table 1.

Patient characteristics.

Treatment characteristics Treatment p-value
Guselkumab Risankizumab Tildrakizumab All treatments
Total number of treatments/patients 127 55 15 197
Characteristic at start of treatment Number (%) of females 44 (34.6) 19 (34.5) 4 (26.7) 67 (34.0) 0.891
Mean age (SD) 46.0 (14.2) 47.9 (11.6) 45.9 (14.1) 46.5 (13.5) 0.668
Mean PASI (SD) in biologic naïve patients 9.63 (6.59) 11.13 (6.67) 11.67 (11.08) 10.25 (7.23) 0.545
Mean PASI (SD) in biologic non-naïve patients 7.80 (7.52) 9.13 (8.10) 9.13 (5.22) 8.01 (7.44) 0.700
Number (%) of patients with PASI ≤ 3 37 (29.1) 12 (21.8) 3 (20.0) 52 (26.4) 0.496812
Number (%) of cycles in patients with arthritis 31 (24.4) 19 (34.5) 1 (6.7) 51 (25.9) 0.077
Mean weight in kg (SD) 92.0 (19.2) 88.9 (13.4) 94.4 (11.8) 91.3 (17.4) 0.736
Mean BMI (SD) 30.0 (6.5) 29.3 (4.4) 29.9 (2.3) 29.8 (5.6) 0.914
Number (%) of patient with the last previous biologic treatment None 54 (42.5) 29 (52.7) 11 (73.3) 94 (47.7) 0.068
TNF-alpha 14 (11.0) 6 (10.9) 0 (0) 20 (10.2)+ 
IL-12/23 33 (26.0) 5 (9.1) 2 (13.3) 40 (20.3)*
IL-17 26 (20.5) 15 (27.3) 2 (13.3) 43 (21.8)#
Number (%) of previous biologic therapies 1 41 (55.4) 13 (50.0) 2 (50.0) 56 (53.8) 0.767
2 14 (18.9) 8 (30.8) 1 (25.0) 23 (22.1)
 ≥ 3 19 (25.7) 5 (19.2) 1 (25.0) 25 (24.0)

Analysis of variances and chi-square test did not reveal differences in allocation to treatment regarding sex, age, PASI, psoriatic arthritis, or (type of) previous biologic exposure. Chi-square test results revealed that a previous treatment with TNF-alpha and IL-12/23 inhibitors were the first biologic treatments for a significantly higher proportion of patients (p = 0.000778).

+Seven patients (35.0%) were biologic-non-naïve when treated with TNF-alpha inhibitors.

*Ten patients (25.0%) were biologic-non-naïve when treated with IL-12/23 inhibitors.

#Twenty-eight patients (65.1%) were biologic-non-naïve when treated with IL-17 inhibitors.

BMI, body mass index; IL, interleukin; PASI, Psoriasis Area and Severity Index; SD, standard deviation; TNF, tumour necrosis factor.